QuadMedicine Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	7,143	10,698	9,304	1,012
Revenue Growth	-46.49%	14.99%	819.58%	-
Gross Profit	7,143	10,698	9,304	1,012
Selling, General & Admin	2,271	1,826	1,337	1,413
Research & Development	14,357	15,014	12,269	9,006
Other Operating Expenses	72.69	73.63	2.75	2.91
Operating Expenses	16,995	17,082	13,753	10,531
Operating Income	-9,852	-6,384	-4,449	-9,519
Interest Expense	-343.39	-349.97	-370.45	-114.15
Interest & Investment Income	237.47	90.26	23.9	107.11
Currency Exchange Gain (Loss)	91.18	-42.06	129.9	20.89
Other Non Operating Income (Expenses)	-228.19	-228.99	-302.32	-249.92
EBT Excluding Unusual Items	-10,095	-6,915	-4,968	-9,755
Gain (Loss) on Sale of Assets	-16.34	-16.34	-	-3.14
Pretax Income	-10,108	-6,931	-4,968	-9,759
Net Income	-10,108	-6,931	-4,968	-9,759
Net Income to Common	-10,108	-6,931	-4,968	-9,759
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	11	10	9	9
Shares Outstanding (Diluted)	11	10	9	9
Shares Change	17.91%	10.16%	0.94%	-
EPS (Basic)	-948.62	-721.76	-569.92	-1129.97
EPS (Diluted)	-948.83	-722.00	-570.00	-1130.00
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-9,725	-6,738	-2,214	-10,056
Free Cash Flow Per Share	-912.70	-701.66	-253.98	-1164.44
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-137.93%	-59.67%	-47.82%	-940.90%
Profit Margin	-141.51%	-64.79%	-53.40%	-964.54%
Free Cash Flow Margin	-136.15%	-62.98%	-23.80%	-993.97%
EBITDA	-6,332	-3,088	-1,297	-7,448
EBITDA Margin	-88.64%	-28.87%	-13.94%	-
D&A For EBITDA	3,521	3,296	3,153	2,071
EBIT	-9,852	-6,384	-4,449	-9,519
EBIT Margin	-137.93%	-59.67%	-47.82%	-